mavaCamten Observational evidence Global cOnsortium in HCM [COLLIGO-HCM] (NCT06372457)

The aim of this study is to investigate treatments and real-world effectiveness for hypertrophic cardiomyopathy (HCM), including examining the path to diagnosis, disease progression, and the new treatment for obstructive HCM (o-HCM), mavacamten. This protocol localisation for COLLIGO-HCM is for The Alfred Hospital participating site in Australia. It will address only a subset of the objectives from the master protocol which were deemed applicable after conducting feasibility.

Trial phase

Phase 4

Trial participation type

This trial has been designed for Registry.

Principal investigator

Dr Elizabeth Paratz

Key inclusion data

Two analytic subcohorts will be identified from the source cohort: 1. The HCM subcohort will include all patients in the source cohort with an available HCM diagnosis date and without evidence of an HCM phenocopy (athlete’s heart, hypertensive heart disease, Fabry disease, Pompe disease, Danon disease, amyloidosis) after the first observed HCM-associated encounter in the medical record. 2. The mavacamten subcohort will include all patients in the source cohort who were treated with mavacamten.